Cytokeratin 17 (KRT17) Mouse Monoclonal Antibody [Clone ID: Ks 17.E3]

CAT#: TA327663

Mouse Monoclonal Cytokeratin 17 Antibody

Product Images

Immunohistochemistry staining of Paraffin Cervix neoplasia III tissue by Cytokeratin 17 antibody (dilution: 1:25 - 1:100; visualization of staining: Cytoplasmic)

Specifications

Product Data

• Clone Name: Ks 17.E3
• Applications: IHC
• Recommended Dilution: IHC: 1:25 - 1:100
• Reactivities: Human
• Host: Mouse
• Isotype: IgG2b
• Clonality: Monoclonal
• Formulation: This antibody is supplied as cell culture supernatant diluted in tris buffered saline, pH 7.3-7.7, with 1% BSA and <0.1% sodium azide.
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Gene Name: keratin 17
• Database Link:
  NP_000413
  Entrez Gene 3872 Human
  UniProt ID Q04695
• Synonyms: 39.1; CK-17; K17; PC; PC2; PCHC1
• Note: Cytokeratin 17 (CK 17) is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as “epithelial stem cell” marker because CK 17 antibody marks basal cell differentiation. CK 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK 5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK 17. Also important is that cases of triple negative breast carcinoma with expression of CK 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK 17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.